Latest Whitepapers

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Innovation is key for any biopharmaceutical and biotechnology company. Whilst the demand for infectious disease prevention continues to grow, so does the pressure on these companies to deliver innovative solutions.

In this whitepaper, learn how the innovative features of the cobas t 711 coagulation analyzer address the need for greater efficiency, improved workflow and reliable results, potentially allowing laboratory staff to gain more time to focus on validation and clinical interpretation.

Process development teams need detailed information, via a platform that delivers short gradients to allow the required sample throughput to detect HCPs in a low sub-ppm range.

Flow cytometry is an important part of the drug discovery workflow. From screening antibodies to small molecules, combining tests for various analytes in a single panel not only reduces the necessary sample volume but also collects more information in less time, accelerating the drug discovery process.

The EU GMP Annex 1 provides specific guidance on the manufacture of sterile medicinal products. Though it is a European guide for manufacturing, EU GMP Annex 1’s impact is global. So how does the latest revision affect you?

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Recent technological advancements have made single-cell sequencing an increasingly powerful tool for understanding biology and cellular function, disease diagnosis, therapy response prediction, and treatment selection.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Biofuels have garnered increased attention due to the economic and environmental concerns associated with petroleum-based fuel.